Disease Mongering_Conference / PLoS Special Issue
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
A front page report in The New York Times provides additonal information about the catastrophic TGN1412 medical experiment in which 6 previously healthy volunteers were intravenously injected with monoclonal antibody in a highly risky procedure.
The independent Institute of Science in Society (ISIS) challenges the report issued by the UK government medicines oversight agency, MHRA (equivalent to US FDA), absolving itself and those involved from any responsibility for a catastrophic human experiment that nearly killed six healthy volunteers.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released an interim report about the near fatal clinical trial of the monoclonal antibody, TGN1412, stating:
Psychiatry’s professional practice paradigm has received a major blow.
A report in The New Scientist, "Prescribing of Hyperactivity Drugs is Out of Control," shows just how deviant U.S. prescribing of psychostimulants for
children is compared to the rest of the world.
An OpEd in The New York Times (below) is trumpeting psychiatry’s latest “cure” for depression: it requires surgical implantation of electrodes in the brain, continued “maintenance” with powerful psychotropic drugs, and it costs $40,000.
The truth about the pharmaceutical industry and its corrupting influence on high ranking lawmakers and the near-total subversion of the FDA is spreading to the American hinterland. Below is an informed, intelligent editorial in the Shreveport Times, Louisiana that explains to readers why this industry is not to be trusted.
Amphetamines work like Cocaine–first and foremost, they are addictive. The psychostimulant drugs prescribed for millions of American children labeled ADHD, are amphetamines and are, therefore, addictive.
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
Unless Congress acts to overrule the FDA, research disasters such as occurred in London, when six healthy men were exposed to an experimental substance that brought them close to death, are likely to occur with increased frequency.